The T Cell Specific Surface Glycoprotein CD28 pipeline drugs market research report outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the T Cell Specific Surface Glycoprotein CD28 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Ophthalmology which include the indications Solid Tumor, Gastric Cancer, Kidney Transplant Rejection, Heart Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes), and Uveitis. It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 targeted therapeutics development with respective active and dormant or discontinued products.
The T Cell Specific Surface Glycoprotein CD28 pipeline targets constitutes close to 40 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 8, 7, 17, and 3 respectively. Similarly, the universities portfolio in Phase II, Phase I, and Phase 0 comprises 1, 2, and 1 molecule.
T Cell Specific Surface Glycoprotein CD28 overview
CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.
For a complete picture of T Cell Specific Surface Glycoprotein CD28’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
